Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry Meeting Abstract
| Authors: | Francini, E.; Yip, S.; Ahmed, N. S.; Li, H.; Ardolino, L.; Evan, C. P.; Kaymakcalan, M.; Shaw, G. K.; Kantoff, P.; Taplin, M. E.; Alimohamed, N.; Joshua, A. M.; Heng, D. Y. C.; Sweeney, C. J. |
| Abstract Title: | Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx370.023 |
| Language: | English |
| ACCESSION: | WOS:000411324001321 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx370.023 |
| Notes: | Meeting Abstract: 806P -- Appears on pages 278-279 of the abstract book -- Source: Wos |
